ZA200800567B - Compounds for treatment of lipase-mediated diseases - Google Patents

Compounds for treatment of lipase-mediated diseases

Info

Publication number
ZA200800567B
ZA200800567B ZA200800567A ZA200800567A ZA200800567B ZA 200800567 B ZA200800567 B ZA 200800567B ZA 200800567 A ZA200800567 A ZA 200800567A ZA 200800567 A ZA200800567 A ZA 200800567A ZA 200800567 B ZA200800567 B ZA 200800567B
Authority
ZA
South Africa
Prior art keywords
lipase
compounds
treatment
mediated diseases
mediated
Prior art date
Application number
ZA200800567A
Other languages
English (en)
Inventor
Upadhyay Shakti
Yadav Raman
Gangan Vijay
Kanekar Yogesh
Original Assignee
Reliance Life Sciences Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliance Life Sciences Pvt Ltd filed Critical Reliance Life Sciences Pvt Ltd
Publication of ZA200800567B publication Critical patent/ZA200800567B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/02—Quinones with monocyclic quinoid structure
    • C07C50/04—Benzoquinones, i.e. C6H4O2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200800567A 2005-07-21 2008-01-18 Compounds for treatment of lipase-mediated diseases ZA200800567B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN864MU2005 2005-07-21

Publications (1)

Publication Number Publication Date
ZA200800567B true ZA200800567B (en) 2008-11-26

Family

ID=36121552

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800567A ZA200800567B (en) 2005-07-21 2008-01-18 Compounds for treatment of lipase-mediated diseases

Country Status (12)

Country Link
EP (1) EP1937622A1 (ja)
JP (1) JP2009505953A (ja)
KR (1) KR100928954B1 (ja)
CN (1) CN101228108A (ja)
AU (1) AU2005334672A1 (ja)
BR (1) BRPI0520515A2 (ja)
CA (1) CA2614585A1 (ja)
IL (1) IL188894A0 (ja)
NZ (1) NZ565878A (ja)
RU (1) RU2420513C2 (ja)
WO (1) WO2007010546A1 (ja)
ZA (1) ZA200800567B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
AU2014230640B2 (en) * 2013-03-14 2018-08-16 Shionogi & Co., Ltd. Monoclonal antibody inhibiting enzymatic activity of endothelial lipase
JP2016534049A (ja) * 2013-10-08 2016-11-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ 内皮リパーゼ阻害を示す官能基化フラン−２−スルホンアミド
US10259804B2 (en) 2014-09-26 2019-04-16 Shifa Biomedical Corporation Anti-endothelial lipase compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7510536A (en) * 1975-09-05 1977-03-08 Council Scient Ind Res Salts of embelin with primary amines
DE2540282A1 (de) * 1975-09-10 1977-03-24 Council Scient Ind Res Kondensationsprodukt von embelin mit einem primaeren amin und verfahren zu seiner herstellung
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases

Also Published As

Publication number Publication date
NZ565878A (en) 2010-04-30
JP2009505953A (ja) 2009-02-12
RU2420513C2 (ru) 2011-06-10
CN101228108A (zh) 2008-07-23
RU2008106628A (ru) 2009-08-27
KR20080030044A (ko) 2008-04-03
BRPI0520515A2 (pt) 2009-05-12
AU2005334672A1 (en) 2007-01-25
KR100928954B1 (ko) 2009-11-30
EP1937622A1 (en) 2008-07-02
CA2614585A1 (en) 2007-01-25
WO2007010546A1 (en) 2007-01-25
IL188894A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
IL194076A0 (en) Imidazolothiazole compounds for the treatment of disease
IL195571A0 (en) Compounds for the treatment of periodontal disease
IL187739A0 (en) New 2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
ZA200800907B (en) Treatment of cancer
IL186578A0 (en) Compositions for treatment of neovascularization diseases
EP2004204A4 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
IL190779A0 (en) Compositions for treatment of eye diseases
EP1962869A4 (en) TREATMENT OF RESPIRATORY DISEASES
EP1987838A4 (en) NEW CONNECTION TO TUMOR THERAPY
IL187715A0 (en) Use of phenylsemicarbazones for seed treatment
GB0610183D0 (en) Treatment of neurodegenerative diseases
GB0518508D0 (en) Treatment of waste
EP1867640A4 (en) MEANS FOR TREATING SOLID TUMORS
GB0605715D0 (en) Treatment of laminitis
IL186904A0 (en) Novel compounds for treating inflammatory diseases
EP1963358A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH THE EPSTEIN-BARR-VIRUS
EP1986656A4 (en) WITHACNISTINE COMPOUNDS FOR THE TREATMENT OF CANCER
IL188894A0 (en) Compounds for treatment of lipase-mediated diseases
GB0400802D0 (en) Compounds for the treatment of disease
GB0520067D0 (en) Treatment of cancer
ZA200707592B (en) Novel compounds for treating inflammatory diseases
IL190182A0 (en) 2-aminoalcohols for the treatment of neurodegenerative diseases
ZA200606780B (en) Compounds for the treatment of diseases
GB0623740D0 (en) Treatment of disease
HU0500947D0 (en) Composition for treatment of paradontosis